Status:
UNKNOWN
Cognitive Protective Effect of Newer Antidiabetic Drugs
Lead Sponsor:
Alexandria University
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
50+ years
Brief Summary
The proposed study aims to: 1. Explore the cognitive protective effects of SGLT2 inhibitors and DPP-4 inhibitors in patients attending diabetic clinics in Alexandria 2. Examine the possible relations...
Detailed Description
The investigators propose to profile diabetic patients taking SGLT2 inhibitors and DPP-4 inhibitors using different parameters and compare them to others on more traditional anti-diabetic therapy. Reg...
Eligibility Criteria
Inclusion
- Type 2 Diabetic Patients
- Age (≥50 Years)
- Ability to understand and cooperate with study procedures
Exclusion
- Diagnosed dementia
- Use of possible or known cognition impairing drugs in the last three months
Key Trial Info
Start Date :
March 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05347459
Start Date
March 2 2022
End Date
December 1 2023
Last Update
July 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alexandria University
Alexandria, Egypt